Moxonidin Actavis (Moxonidine)
Centrally acting antihypertensive for the treatment of essential hypertension
Moxonidin Actavis contains the active substance moxonidine, a centrally acting antihypertensive medication used to treat mild to moderate essential hypertension (high blood pressure not caused by another medical condition). It works by stimulating imidazoline I1 receptors in the brainstem, reducing sympathetic nervous system activity and lowering blood pressure. Available as film-coated tablets in 0.2 mg and 0.4 mg strengths, it requires a prescription and should only be taken under medical supervision.
Quick Facts
Key Takeaways
- Moxonidine is a centrally acting antihypertensive that lowers blood pressure by reducing sympathetic nervous system activity through selective imidazoline I1 receptor stimulation.
- Treatment starts at 0.2 mg daily and can be increased up to a maximum of 0.6 mg per day, with dose adjustments made at three-week intervals based on clinical response.
- The medication must never be stopped abruptly – gradual discontinuation over two weeks is required to prevent rebound hypertension.
- Dry mouth is the most common side effect (affecting more than 1 in 10 patients), but most side effects are mild and often diminish with continued use.
- Moxonidine is contraindicated in patients with heart failure, sick sinus syndrome, second- or third-degree AV block, and resting heart rate below 50 bpm.
What Is Moxonidin Actavis and What Is It Used For?
Moxonidin Actavis belongs to a class of medications known as centrally acting antihypertensive agents. Unlike many other blood pressure medications that work on the heart, blood vessels, or kidneys directly, moxonidine acts primarily in the central nervous system. It selectively stimulates imidazoline I1 receptors located in the rostral ventrolateral medulla (RVLM) of the brainstem, a key regulatory centre for sympathetic nervous system outflow. By reducing sympathetic tone, moxonidine decreases peripheral vascular resistance and subsequently lowers blood pressure.
Essential hypertension – also called primary hypertension – is the most common form of high blood pressure. It accounts for approximately 90–95% of all hypertension cases and develops gradually over many years without a clearly identifiable cause. Risk factors include age, family history, obesity, excessive salt intake, physical inactivity, and chronic stress. Left untreated, hypertension significantly increases the risk of cardiovascular events including heart attack, stroke, heart failure, and kidney disease.
The European Society of Cardiology (ESC) and European Society of Hypertension (ESH) 2023 guidelines define hypertension as a sustained systolic blood pressure of 140 mmHg or higher and/or a diastolic blood pressure of 90 mmHg or higher. Moxonidine is typically used when first-line treatments (such as ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, or thiazide diuretics) are insufficient or not tolerated, either as monotherapy or in combination with other antihypertensive agents.
One notable advantage of moxonidine over older centrally acting agents (such as clonidine) is its selectivity for imidazoline receptors over alpha-2 adrenergic receptors. This selectivity results in fewer side effects, particularly less sedation and dry mouth, although dry mouth remains the most frequently reported adverse effect. Clinical studies have also shown that moxonidine may have beneficial metabolic effects, including improved insulin sensitivity and favourable effects on lipid profiles, making it potentially useful in patients with metabolic syndrome.
What Should You Know Before Taking Moxonidin Actavis?
Contraindications
You should not take Moxonidin Actavis if you have any of the following conditions:
- Allergy to moxonidine or any of the other ingredients in the tablet (including lactose monohydrate, crospovidone, povidone K25, magnesium stearate, hypromellose, titanium dioxide, macrogol 400, or red iron oxide).
- Sick sinus syndrome – a group of heart rhythm disorders where the sinus node does not function properly.
- Atrioventricular (AV) block grade II or III – conditions where electrical signals between the upper and lower chambers of the heart are partially or completely blocked.
- Bradycardia – a resting heart rate below 50 beats per minute.
- Heart failure – a condition where the heart cannot pump sufficient blood to meet the body’s needs, leading to symptoms such as shortness of breath and leg swelling.
Warnings and Precautions
Speak with your doctor before taking Moxonidin Actavis if any of the following apply to you:
- First-degree AV block – a milder form of heart conduction delay that requires careful monitoring during treatment.
- Coronary artery disease or unstable angina – if you experience chest pain at rest or with minimal exertion, discuss this with your doctor, as moxonidine could affect cardiac blood supply regulation.
- Kidney disease – moxonidine is primarily excreted through the kidneys, so impaired kidney function can lead to higher drug levels in the blood. Your doctor will monitor your blood pressure carefully and may need to adjust the dose.
- Concurrent use of beta-blockers – if you are taking a beta-blocker and both medications need to be discontinued, the beta-blocker must be stopped first, followed by moxonidine several days later. This sequence is critical to prevent dangerous rebound hypertension.
Treatment with Moxonidin Actavis must never be stopped suddenly. Abrupt discontinuation can cause a dangerous rebound increase in blood pressure. Your doctor will guide you through a gradual dose reduction over a two-week period. Always follow your doctor’s instructions for tapering the medication.
Elderly patients: Older adults may be more sensitive to the blood pressure-lowering effects of moxonidine. Doctors typically start with a lower dose and increase it gradually while monitoring for excessive blood pressure reduction, dizziness, or falls.
Children and adolescents: Moxonidin Actavis should not be given to children or adolescents under 16 years of age, as there is insufficient clinical experience in this age group.
Pregnancy and Breastfeeding
Moxonidin Actavis should not be used during pregnancy due to the lack of adequate safety data from clinical studies in pregnant women. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking this medication. Your doctor will assess the benefits and risks and may recommend alternative antihypertensive medications with established safety profiles during pregnancy, such as labetalol, nifedipine, or methyldopa.
Moxonidine passes into breast milk. Therefore, breastfeeding should be discontinued if treatment with Moxonidin Actavis is deemed necessary. Discuss alternative feeding options and blood pressure management strategies with your healthcare provider.
Driving and Operating Machinery
Although no formal studies have been conducted on the effects of moxonidine on driving ability, drowsiness and dizziness have been reported as side effects. If you experience these symptoms, do not drive or operate machinery. You are responsible for assessing your own fitness to drive – consider the effects of this medication alongside any other factors that may impair alertness.
Moxonidin Actavis tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medication.
How Does Moxonidin Actavis Interact with Other Drugs?
Drug interactions can alter how medications work, potentially reducing their effectiveness or increasing the risk of side effects. Because moxonidine acts on the central nervous system and is eliminated primarily through the kidneys, interactions can occur through both pharmacodynamic and pharmacokinetic mechanisms. The following table summarises the most clinically significant interactions:
Major Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Other antihypertensives | Enhanced blood pressure-lowering effect; risk of hypotension | Monitor blood pressure closely; dose adjustment may be needed |
| Beta-blockers | Additive bradycardia and hypotension; rebound hypertension risk on withdrawal | If both need to be stopped, discontinue beta-blocker first, then moxonidine days later |
| Tricyclic antidepressants (e.g., imipramine, amitriptyline) | Moxonidine may increase sedative effect; antidepressants may reduce antihypertensive effect | Concurrent use not recommended |
| Benzodiazepines (e.g., diazepam, lorazepam) | Increased sedative and CNS depressant effects | Use with caution; monitor for excessive drowsiness |
| Tolazoline | May reduce the antihypertensive effect of moxonidine | Avoid concurrent use if possible |
Other Interactions
Because moxonidine is excreted primarily through renal tubular secretion, other medications that use the same excretion pathway may alter moxonidine levels in the blood. These include:
- Sulphonylureas and insulin – medications used for diabetes management.
- Nitrates – used for the treatment of angina pectoris (chest pain).
- Cardiac glycosides (digoxin, digitoxin) – used for heart failure and certain arrhythmias.
- Anti-rheumatic medications – various drugs used for inflammatory joint conditions.
- Lipid-lowering agents – medications to reduce blood cholesterol levels.
- Allopurinol, probenecid, colchicine – medications used in the treatment of gout.
- Cimetidine – used for heartburn and peptic ulcers.
- Thyroid extracts – used for underactive thyroid (hypothyroidism).
Moxonidine may enhance the effects of alcohol. It is advisable to limit or avoid alcohol consumption during treatment. Alcohol can increase the blood pressure-lowering effect and exacerbate side effects such as dizziness, drowsiness, and impaired coordination.
Food and administration: Moxonidin Actavis may be taken before, during, or after meals. Swallow the tablet whole with a sufficient amount of water (a full glass). Food does not significantly affect the absorption or effectiveness of the medication.
What Is the Correct Dosage of Moxonidin Actavis?
Always take Moxonidin Actavis exactly as your doctor has instructed. The dosage is individualised based on your blood pressure response and tolerance. Do not change your dose without consulting your doctor first.
Adults
Starting Dose
0.2 mg moxonidine once daily. The tablet should be taken at the same time each day, preferably in the morning, with a glass of water.
Dose Titration (after 3 weeks)
If blood pressure control is not adequate after three weeks, your doctor may increase the dose to 0.4 mg daily, taken as a single dose or split into two doses (morning and evening).
Maximum Dose (after further 3 weeks)
If the desired effect is still not achieved, the dose may be increased to 0.6 mg daily, given as 0.3 mg twice daily (morning and evening). The maximum single dose at any one time is 0.4 mg, and the maximum total daily dose is 0.6 mg.
| Patient Group | Starting Dose | Maximum Daily Dose | Notes |
|---|---|---|---|
| Adults | 0.2 mg once daily | 0.6 mg (0.3 mg twice daily) | Increase at 3-week intervals |
| Elderly (normal kidney function) | 0.2 mg once daily | 0.6 mg | Same as adults; monitor closely for hypotension |
| Moderate kidney impairment | 0.2 mg once daily | 0.4 mg | Dose adjustment required; careful monitoring |
| Severe kidney impairment | 0.2 mg once daily | 0.3 mg | Close medical supervision essential |
| Mild-moderate liver impairment | 0.2 mg once daily | 0.6 mg | Same as adults |
| Children (<16 years) | Not recommended | N/A | Insufficient clinical data |
Elderly Patients
Elderly patients with normal kidney function can follow the same dosing recommendations as other adults. However, older adults are generally more susceptible to blood pressure-lowering effects and may experience more pronounced hypotension, dizziness, or falls. Doctors will typically start with the lowest available dose and increase gradually, with frequent blood pressure monitoring especially during the initial titration phase.
Children and Adolescents
Moxonidin Actavis should not be used in children and adolescents under 16 years of age. There is insufficient clinical experience and safety data to support its use in this population. If a child or adolescent requires antihypertensive treatment, a paediatrician or paediatric cardiologist should recommend an appropriate alternative medication with an established safety profile in younger patients.
Missed Dose
If you forget to take a dose of Moxonidin Actavis, do not take a double dose to compensate. Simply take the next scheduled dose at the usual time. Taking a double dose could result in excessive blood pressure lowering, potentially causing dizziness, lightheadedness, fainting, or other symptoms of hypotension. If you frequently forget to take your medication, consider setting a daily alarm or using a pill organiser to help maintain your dosing schedule.
Overdose
If you have taken more moxonidine than prescribed, or if a child has accidentally ingested the medication, contact your doctor, hospital, or poison control centre immediately for risk assessment and guidance.
Signs of overdose in adults include: headache, drowsiness, sedation, low blood pressure (both at rest and when changing position, which may cause dizziness and confusion), weakness, slow heart rate, dry mouth, vomiting, fatigue, and abdominal pain. In severe cases, respiratory depression and reduced consciousness may occur.
Signs of overdose in children include: sleepiness, constricted pupils (miosis), low blood pressure, respiratory difficulties, and in severe cases, coma. Children are particularly vulnerable to accidental ingestion, so tablets should always be stored out of reach.
What Are the Side Effects of Moxonidin Actavis?
Like all medicines, Moxonidin Actavis can cause side effects, although not everybody gets them. Most side effects are mild to moderate and may improve as your body adjusts to the medication. However, some side effects require immediate medical attention.
Stop taking Moxonidin Actavis and contact your doctor immediately if you experience any signs of angioedema: swelling of the face, tongue, or throat; difficulty swallowing; hives (urticaria); or breathing difficulties. This is a potentially life-threatening allergic reaction that requires urgent medical treatment.
Very Common
Affects more than 1 in 10 patients
- Dry mouth (xerostomia)
Common
Affects 1 to 10 in 100 patients
- Cognitive impairment (difficulty thinking clearly)
- Sleep disturbances, insomnia
- Drowsiness, lethargy
- Headache, dizziness, vertigo
- Nausea, vomiting, diarrhoea, constipation, gastrointestinal discomfort
- Fatigue, weakness (asthenia)
- Vasodilation (flushing, mild skin redness)
- Back pain
- Skin rash, itching (pruritus)
Uncommon
Affects 1 to 10 in 1,000 patients
- Gynaecomastia (breast enlargement in men), erectile dysfunction, decreased libido
- Depression, anxiety, nervousness, fainting (syncope)
- Dry, itchy, burning eyes
- Tinnitus (ringing in the ears)
- Neck pain, parotid gland pain
- Bradycardia (slow heart rate)
- Angioedema (swelling under the skin), allergic reactions
- Urinary retention or urinary incontinence
- Peripheral oedema (fluid retention), leg weakness
- Brief episodes of loss of consciousness
- Loss of appetite
- Hypotension, orthostatic hypotension (blood pressure drop on standing)
- Paraesthesia (tingling in arms and legs)
- Raynaud’s phenomenon (painful whitening of fingers and toes followed by redness)
- Peripheral circulatory disturbances
Rare
Affects fewer than 1 in 10,000 patients
- Hepatitis (liver inflammation)
- Cholestasis (blocked bile secretion) causing abdominal pain, jaundice (yellowing of skin and eyes), skin itching
If you experience any side effects not listed here, or if any of the side effects become severe or persistent, talk to your doctor or pharmacist. Reporting side effects helps regulatory agencies continuously monitor the benefit-risk balance of medications.
How Should You Store Moxonidin Actavis?
Proper storage of medications ensures they remain effective and safe throughout their shelf life. Moxonidin Actavis should be stored under the following conditions:
- Temperature: Store at or below 30°C (86°F). Do not refrigerate or freeze.
- Light protection: Keep the tablets in the original blister packaging to protect them from light, as moxonidine is light-sensitive.
- Child safety: Keep this medication out of the sight and reach of children at all times. The tablets could be dangerous if accidentally ingested by children.
- Expiry date: Do not use the medication after the expiry date (EXP) printed on the blister pack and outer carton. The expiry date refers to the last day of the stated month.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused or expired medicines to your pharmacy for environmentally safe disposal.
What Does Moxonidin Actavis Contain?
Understanding the full composition of your medication is important, particularly if you have known allergies or intolerances to specific ingredients. The tables below detail both the active and inactive components of Moxonidin Actavis tablets.
Active Ingredient
Each film-coated tablet contains moxonidine as the active substance. It is available in two strengths:
- 0.2 mg tablets – light pink, round film-coated tablets
- 0.4 mg tablets – dark pink, round film-coated tablets
Inactive Ingredients (Excipients)
| Component | Ingredient | Function |
|---|---|---|
| Tablet core | Lactose monohydrate | Filler/diluent |
| Tablet core | Crospovidone | Disintegrant |
| Tablet core | Povidone K25 | Binder |
| Tablet core | Magnesium stearate | Lubricant |
| Film coating | Hypromellose | Film-forming agent |
| Film coating | Titanium dioxide (E171) | Colourant/opacifier |
| Film coating | Macrogol 400 | Plasticiser |
| Film coating | Red iron oxide (E172) | Colourant |
Available pack sizes: Moxonidin Actavis is supplied in blister packs containing 10, 20, 28, 30, 50, 98, or 100 film-coated tablets. Hospital packs of 400 tablets (20 × 20 or 10 × 40) are also available. Not all pack sizes may be marketed in every country.
Marketing Authorisation Holder: Actavis Group PTC ehf., Dalshraun 1, IS-220 Hafnarfjordur, Iceland. The tablets are manufactured by Chanelle Medical (Loughrea, Ireland), Rottendorf Pharma GmbH (Ennigerloh, Germany), and Merckle GmbH (Ulm, Germany).
Frequently Asked Questions
Moxonidin Actavis is used to treat mild to moderate essential hypertension (high blood pressure that is not caused by another medical condition). It works by acting on the central nervous system to reduce the activity of the sympathetic nervous system, which in turn lowers blood pressure. It is typically prescribed when first-line treatments are not sufficient or not tolerated, either alone or in combination with other blood pressure-lowering medications.
No. You should never stop taking Moxonidin Actavis abruptly. Sudden discontinuation can lead to rebound hypertension – a dangerous and rapid increase in blood pressure that can cause serious cardiovascular events. Your doctor will create a tapering plan to gradually reduce the dose over a two-week period. If you are also taking a beta-blocker, the beta-blocker should be stopped first, followed by moxonidine several days later.
The most common side effect is dry mouth (xerostomia), affecting more than 1 in 10 patients. Other common side effects include headache, dizziness, drowsiness, sleep disturbances, nausea, diarrhoea, constipation, fatigue, back pain, and skin rash. Most of these side effects are mild and may improve as your body adapts to the medication over the first few weeks of treatment. If they persist or become troublesome, speak with your doctor.
Moxonidin Actavis should not be used during pregnancy as there is insufficient safety data. Moxonidine also passes into breast milk, so breastfeeding should be discontinued if treatment is considered necessary. If you are pregnant, planning to become pregnant, or breastfeeding, your doctor can recommend alternative antihypertensive medications with better-established safety profiles, such as labetalol, nifedipine, or methyldopa.
Moxonidine is classified as a centrally acting antihypertensive agent. Unlike first-line options such as ACE inhibitors (e.g., ramipril, enalapril), angiotensin receptor blockers (e.g., losartan, valsartan), calcium channel blockers (e.g., amlodipine), or thiazide diuretics, moxonidine works by reducing sympathetic nervous system activity from the brainstem. It is generally used as a second-line or add-on therapy. One advantage over older centrally acting agents like clonidine is fewer side effects due to its greater selectivity for imidazoline I1 receptors. Studies also suggest it may have beneficial metabolic effects, including improved insulin sensitivity.
If you miss a dose, do not take a double dose to make up for it. Simply skip the missed dose and take the next one at the usual scheduled time. Taking a double dose could cause your blood pressure to drop too low, resulting in dizziness, lightheadedness, or fainting. If you are unsure about what to do, contact your doctor or pharmacist for advice.
References
This article is based on the following peer-reviewed sources and international medical guidelines:
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-3104. Updated 2023.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Updated 2023.
- World Health Organization (WHO). Guideline for the pharmacological treatment of hypertension in adults. Geneva: WHO; 2021.
- Schachter M. Moxonidine: a review of safety and tolerability after seven years of clinical experience. Journal of Hypertension. 1999;17(Suppl 3):S37-S39.
- Prichard BN, Graham BR. The use of moxonidine in the treatment of hypertension. Journal of Hypertension. 1997;15(Suppl 1):S47-S55.
- European Medicines Agency (EMA). Moxonidine – Summary of Product Characteristics. Accessed January 2026.
- Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. International Journal of Clinical Practice. 2006;60(5):621-629.
- British National Formulary (BNF). Moxonidine monograph. NICE Evidence Services. Accessed January 2026.
Editorial Team
This article was written and medically reviewed by the iMedic Medical Editorial Team, a group of board-certified physicians specialising in cardiology, pharmacology, and internal medicine. Our team follows international medical guidelines (ESC/ESH, WHO, NICE) and uses the GRADE evidence framework to ensure all information is accurate, up-to-date, and clinically relevant.
All content undergoes rigorous peer review by at least two independent medical specialists before publication. Every claim is verified against current international guidelines and peer-reviewed research.
iMedic operates with complete editorial independence. We receive no commercial funding, pharmaceutical sponsorship, or advertising revenue. Our sole commitment is to providing accurate, accessible medical information.